Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

WATSON PHARMACEUTICALS INC

Form 4

September 05, 2006

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * JOYCE R TODD			2. Issuer Name and Ticker or Trading Symbol WATSON PHARMACEUTICALS INC [WPI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O WATSON PHARMACE BONNIE CIR	(Month 09/01) MACEUTICALS, INC., 311								Director 10% Owner Softicer (give title Other (specify below) VP, Corp. Controller & Treas.		
CORONA, CA	(Street) A 92880	ment, Date Original Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table I	- Non-Der	ivative Se	curitio	es Acqu	uired, Disposed o	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Ye	ar) Exect	Deemed ation Date, if th/Day/Year)	3. Transactic Code (Instr. 8)	Disposed (Instr. 3,	(A) of (B) 4 and (A) or))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock (Restricted)	09/01/2006			A	1,333	A	\$ 0	2,333	D		
Common Stock, par value \$0.0033								6,207	I	Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number out Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		88 II S
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options to Purchase Common Stock (2)	\$ 25.64	09/01/2006		A	4,000	(3)	09/01/2016	Common Stock, par value \$0.0033	4,000	

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

JOYCE R TODD C/O WATSON PHARMACEUTICALS, INC. 311 BONNIE CIRCLE CORONA, CA 92880

VP, Corp. Controller & Treas.

Signatures

/s/R. TODD JOYCE 09/01/2006

**Signature of Date

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted shares of common stock, par value \$0.0033, were issued pursuant to the provisions of the Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. (including, but not limited to, restrictions on transferability and certain forfeiture provisions concerning unvested restricted shares). The restricted shares vest (i) fifty percent on the second anniversary of the

Reporting Owners 2

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

date of grant, and (ii) fifty percent on the fourth anniversary of the date of grant.

- (2) The options are to be incentive stock options to the extent permitted by law, and thereafter to be non-statutory stock options.
- (3) These stock options shall become exercisable in four equal annual installments commencing on September 1, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.